Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
WATERTOWN, Mass., May 30, 2017 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 08:00 a.m. Eastern Time at the Grand Hyatt Hotel in New York City.
A live audio webcast of the Jefferies presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206-899-4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
